Human Genome Sciences, Inc.

Other

Beatson Institute for Cancer Research

Theodora W Salcedo

Craig A Rosen

Steven M Ruben

Tristan J Vaughan

Claire Louise Dobson

Vivian Albert

Vikram P Patel

Gerard John Graham

Robert John Benjamin Nibbs

Tristan John Vaughan

Clarie Louise Dobson

The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.

Methods of treating cancer using antibodies that immunospecifically bind to trail receptors

The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.

Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors

Antibodies that immunospecifically bind to trail receptors

The present invention relates to deletion and substitution mutant polypeptides of human chemokine &#x3b2;-7 (Ck&#x3b2;-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ck&#x3b2;-7, as well as deletion and substitution mutants, in medical treatment regimens. In particular, the Ck&#x3b2;-7 polypeptides described herein may be employed to treat a variety of conditions, including rheumatoid arthritis, inflammation, respiratory diseases, allergy, and IgE-mediated allergic reactions.

Chemokine &#x3b2;-7 variants

The present invention relates to deletion and substitution mutant polypeptides of human chemokine &bgr;-7 (Ck&bgr;-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ck&bgr;-7, as well as deletion and substitution mutants, in medical treatment regimens. In particular, the Ck&bgr;-7 polypeptides described herein may be employed to treat a variety of conditions, including rheumatoid arthritis, inflammation, respiratory diseases, allergy, and IgE-mediated allergic reactions.

Human chemokine &bgr;-7 deletion and substitution proteins

Growing community of inventors

Gaithersburg, MD, United States of America

Theodora W Salcedo